World Investment Advisors LLC Has $6.69 Million Position in Zoetis Inc. (NYSE:ZTS)

World Investment Advisors LLC raised its position in Zoetis Inc. (NYSE:ZTS - Free Report) by 29.1% during the third quarter, according to its most recent 13F filing with the SEC. The fund owned 34,236 shares of the company's stock after buying an additional 7,709 shares during the period. World Investment Advisors LLC's holdings in Zoetis were worth $6,689,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Diamant Asset Management Inc. raised its stake in shares of Zoetis by 2.4% during the third quarter. Diamant Asset Management Inc. now owns 4,465 shares of the company's stock worth $872,000 after buying an additional 105 shares during the last quarter. TD Private Client Wealth LLC lifted its stake in shares of Zoetis by 10.5% in the 3rd quarter. TD Private Client Wealth LLC now owns 11,640 shares of the company's stock valued at $2,274,000 after purchasing an additional 1,106 shares during the period. Toronto Dominion Bank lifted its stake in shares of Zoetis by 18.8% in the 3rd quarter. Toronto Dominion Bank now owns 233,486 shares of the company's stock valued at $45,618,000 after purchasing an additional 37,013 shares during the period. Coldstream Capital Management Inc. grew its stake in shares of Zoetis by 5.6% during the third quarter. Coldstream Capital Management Inc. now owns 33,204 shares of the company's stock worth $6,468,000 after purchasing an additional 1,752 shares during the period. Finally, Geode Capital Management LLC increased its holdings in Zoetis by 1.8% in the third quarter. Geode Capital Management LLC now owns 10,427,760 shares of the company's stock valued at $2,030,813,000 after purchasing an additional 185,364 shares during the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

Zoetis Stock Performance

Zoetis stock traded down $1.18 during mid-day trading on Friday, hitting $177.66. 870,778 shares of the company's stock traded hands, compared to its average volume of 2,528,787. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $201.92. The stock has a market cap of $80.15 billion, a price-to-earnings ratio of 34.05, a P/E/G ratio of 2.89 and a beta of 0.89. The firm has a 50 day simple moving average of $180.82 and a two-hundred day simple moving average of $181.12. The company has a debt-to-equity ratio of 1.26, a current ratio of 3.69 and a quick ratio of 2.27.

Zoetis (NYSE:ZTS - Get Free Report) last announced its earnings results on Monday, November 4th. The company reported $1.58 EPS for the quarter, topping the consensus estimate of $1.46 by $0.12. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The business had revenue of $2.40 billion during the quarter, compared to the consensus estimate of $2.29 billion. During the same quarter in the previous year, the firm posted $1.36 EPS. Zoetis's revenue was up 11.6% compared to the same quarter last year. On average, research analysts expect that Zoetis Inc. will post 5.9 EPS for the current fiscal year.

Zoetis Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, January 21st will be given a $0.50 dividend. This is an increase from Zoetis's previous quarterly dividend of $0.43. This represents a $2.00 annualized dividend and a dividend yield of 1.13%. Zoetis's dividend payout ratio is presently 32.33%.

Analyst Upgrades and Downgrades

ZTS has been the subject of several analyst reports. JPMorgan Chase & Co. boosted their target price on Zoetis from $225.00 to $230.00 and gave the stock an "overweight" rating in a research report on Friday, October 11th. UBS Group started coverage on shares of Zoetis in a report on Monday. They set a "neutral" rating and a $196.00 price objective for the company. Leerink Partnrs upgraded shares of Zoetis to a "strong-buy" rating in a report on Monday, December 2nd. Leerink Partners assumed coverage on shares of Zoetis in a report on Monday, December 2nd. They issued an "outperform" rating and a $215.00 price target for the company. Finally, Stifel Nicolaus raised their price objective on Zoetis from $200.00 to $210.00 and gave the stock a "buy" rating in a research note on Wednesday, September 18th. One equities research analyst has rated the stock with a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average price target of $216.70.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.